Synthetic lethal (SL) pairs are pairs of genes whose simultaneous loss-of-function results in cell death, while a damaging mutation of either gene alone does not affect the cell's survival. This makes SL pairs attractive targets for precision cancer therapies, as targeting the unimpaired gene of the SL pair can selectively kill cancer cells that already harbor the impaired gene. Limited by the difficulty of finding true SL pairs, especially on specific cell types, current computational approaches provide only limited insights because of overlooking the crucial aspects of cellular context dependency and mechanistic understanding of SL pairs. As a result, the identification of SL targets still relies on expensive, time-consuming experimental approaches. In this work, we applied cell-line specific multi-omics data to a specially designed deep learning model to predict cell-line specific SL pairs. Through incorporating multiple types of cell-specific omics data with a self-attention module, we represent gene relationships as graphs. Our approach achieves the prediction of SL pairs in a cell-specific manner and demonstrates the potential to facilitate the discovery of cell-specific SL targets for cancer therapeutics, providing a tool to unearth mechanisms underlying the origin of SL in cancer biology. The code and data of our approach can be found at https://github.com/promethiume/SLwise.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618116PMC
http://dx.doi.org/10.1016/j.csbj.2023.10.011DOI Listing

Publication Analysis

Top Keywords

synthetic lethal
8
cell-line specific
8
pairs
7
graph-based model
4
model identify
4
identify cell
4
specific
4
cell specific
4
specific synthetic
4
lethal effects
4

Similar Publications

CRISPR/Cas9 Technology Providing the Therapeutic Landscape of Metastatic Prostate Cancer.

Pharmaceuticals (Basel)

November 2024

Department of Biochemistry, College of Medicine, Gachon University, Incheon 21999, Republic of Korea.

Prostate cancer (PCa) is the most prevalent malignancy and the second leading cause of cancer-related death in men. Although current therapies can effectively manage the primary tumor, most patients with late-stage disease manifest with metastasis in different organs. From surgery to treatment intensification (TI), several combinations of therapies are administered to improve the prognosis of patients with metastatic PCa.

View Article and Find Full Text PDF

Essential genes, estimated at approximately 20% of the genome, are broadly expressed and required for reproductive success. They are difficult to study, as interfering with their function leads to premature death. Transcription is one of the essential functions of life, and the multi-protein Mediator complex coordinates the regulation of gene expression at nearly every eukaryotic promoter.

View Article and Find Full Text PDF

The SNF2 family chromatin remodeler HELLS has emerged as an important regulator of cell proliferation, genome stability, and several cancer pathways. Significant upregulation of HELLS has been reported in 33 human cancer types. While HELLS has been implicated in DNA damage response, its function in DNA repair is poorly understood.

View Article and Find Full Text PDF

FHIT is a fragile site tumor suppressor that is primarily inactivated upon tobacco smoking. FHIT loss is frequently observed in lung cancer, making it an important biomarker for the development of targeted therapy for lung cancer. Here, we report that inhibitors of glycogen synthase kinase 3 beta (GSK3β) and the homologous recombination DNA repair (HRR) pathway are synthetic lethal with FHIT loss in lung cancer.

View Article and Find Full Text PDF

Discovery of 2(1)-Quinoxalinone Derivatives as Potent and Selective MAT2A Inhibitors for the Treatment of MTAP-Deficient Cancers.

J Med Chem

January 2025

Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.

Article Synopsis
  • MAT2A is a promising target for cancer treatment, especially in tumors with MTAP gene deletion, but there are challenges in ensuring the selectivity of MAT2A inhibitors for these specific cancers.
  • Recent research led to the identification of new MAT2A inhibitors with a unique 2(1)-quinoxalinone structure that effectively inhibit MAT2A and selectively target MTAP-deficient cancer cells.
  • One of the novel compounds demonstrated strong pharmacokinetic properties and showed enhanced anticancer effects in models with MTAP-deficient tumors, highlighting potential advancements in drug development for these cancer types.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!